Health and Aging Brain among Latino Elders (HABLE-AT(N)) Study

拉丁裔老年人的健康与大脑老化 (HABLE-AT(N)) 研究

• 批准号: 10640235
• 负责人: LEIGH A JOHNSON
• 金额: $ 907.47万
• 依托单位: UNIVERSITY OF NORTH TEXAS HLTH SCI CTR
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-08-01 至 2025-04-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10640235
• 关键词: Address; Age of Onset; Alleles; Alzheimer' s Disease; Alzheimer' s disease pathology; Alzheimer' s disease related dementia; Amyloid; Amyloid beta-42; Biological; Biological Assay; Biological Markers; Blood; Cerebrum; Classification; Clinical; Clinical Trials; Cognitive; Cognitive aging; Communities; Data; Dementia; Diabetes Mellitus; Diagnosis; Diagnostic; Disease Progression; Elderly; Enrollment; Ethnic Origin; Frequencies; Goals; Growth; Health; Hispanic; Hispanic Populations; Impaired cognition; Infrastructure; Latino; Latino Population; Magnetic Resonance Imaging; Measures; Mental Depression; Methods; Mexican Americans; Nerve Degeneration; Not Hispanic or Latino; Outcome; Parents; Patients; Pilot Projects; Plasma; Population; Positron-Emission Tomography; Prevalence; Prevalence Study; Primary Prevention; Proteomics; Publications; Race; Research; Risk; Risk Factors; Science; Secondary Prevention; Statistical Models; System; Testing; Underrepresented Populations; Underserved Population; Work; aging brain; apolipoprotein E-4; blood-based biomarker; caucasian American; clinical diagnosis; cohort; cost; design; differential expression; exosome; experience; follow-up; health disparity; mild cognitive impairment; modifiable risk; multi-ethnic; neuroimaging; novel; pre-clinical; prevent; primary care setting; prodromal Alzheimer' s disease; screening; specific biomarkers; tau Proteins; tertiary prevention; tool

PROJECT SUMMARY The 2018 NIA - Alzheimer's Association Research Framework [AT(N)] for Alzheimer's Disease (AD) provides a biological context for studying AD by incorporating state-of-the art biomarkers of amyloid (A), tau (T) and neurodegeneration (N). Despite the fact that these biomarkers vary by race/ethnicity, no prior work has systematically examined them among Mexican Americans. Given that (1) Hispanic/Latinos are projected to experience the largest growth in AD and Alzheimer's Disease Related Dementias (ADRDs) by 2060 and (2) Mexican Americans are the largest segment of the U.S. Hispanic/Latino population, there is a pressing need to study prevalence, progression and clinical impact of these biomarkers among this underrepresented group. This work addresses goals of the National Alzheimer's Project Act (NAPA), NIA Milestones for AD and ADRD research, and needs highlighted by the AT(N) framework publication. The current research team consists of leading experts in Mexican American cognitive aging, neuroimaging (PET and MRI), blood-based biomarkers as well as advanced statistical modeling. By leveraging the ongoing HABLE cohort, infrastructure and data, we will test the following Specific Aims: Aim 1: Examine the prevalence, progression and clinical impact of cerebral markers of the 2018 AT(N) framework among community-dwelling Mexican Americans. Aim 2. Examine the prevalence, progression and clinical impact of blood markers of the 2018 AT(N) framework among community-dwelling Mexican Americans. Aim 3: To determine if blood-based biomarkers of Aβ40, Aβ42, tau and NfL can be used to screen for AT(N)-defined preclinical AD, prodromal AD and AD dementia for enrollment of Mexican Americans into novel clinical trials. The current study is highly significant for several reasons: (1) This is the first-ever large-scale multi-ethnic study of the AT(N) biomarkers, which is of tremendous importance given the racial/ethnic make-up of the U.S. population; (2) this work directly addresses goals set forth by NAPA as well NIA-Milestones for AD/ADRD science; (3) it will determine if ethnic-specific biomarker trajectories are appropriate and finally, (4) it will generate data and methods for increasing enrollment of Hispanics into clinical trials across the AT(N)-defined spectrum of AD (primary, secondary and tertiary prevention) beginning in primary care settings.

项目概要 2018 年 NIA - 阿尔茨海默病协会针对阿尔茨海默病 (AD) 的研究框架 [AT(N)] 提供了 通过结合最先进的淀粉样蛋白 (A)、tau (T) 和 tau (T) 生物标志物来研究 AD 的生物学背景 神经变性（N）。尽管这些生物标志物因种族/民族而异，但之前没有任何研究表明 对墨西哥裔美国人进行了系统的研究。鉴于 (1) 西班牙裔/拉丁裔预计 到 2060 年，AD 和阿尔茨海默病相关痴呆症 (ADRD) 的发病率将出现最大增长，并且 (2) 墨西哥裔美国人是美国西班牙裔/拉丁裔人口中最大的一部分，迫切需要 研究这些生物标志物在这一代表性不足的群体中的患病率、进展和临床影响。 这项工作致力于实现国家阿尔茨海默病项目法案 (NAPA)、NIA AD 和 ADRD 里程碑的目标 AT(N) 框架出版物强调的研究和需求。 目前的研究团队由墨西哥裔美国人认知衰老、神经影像学领域的顶尖专家组成 （PET 和 MRI）、血液生物标志物以及先进的统计模型。通过利用持续的 HABLE 队列、基础设施和数据，我们将测试以下具体目标： 目标 1：检查 2018 AT(N) 框架中脑标志物的患病率、进展和临床影响 居住在社区的墨西哥裔美国人。目标 2. 检查疾病的患病率、进展和临床影响 居住在社区的墨西哥裔美国人中 2018 年 AT(N) 框架的血液标记物。目标 3： 确定基于血液的 Aβ40、Aβ42、tau 和 NfL 生物标志物是否可用于筛查 AT(N) 定义的 墨西哥裔美国人参加新型临床试验的临床前 AD、前驱 AD 和 AD 痴呆。 当前的研究具有非常重要的意义，原因如下：（1）这是有史以来第一个大规模的多民族研究 AT(N) 生物标志物的研究，考虑到美国的种族/民族构成，这一点非常重要。 人口; (2) 这项工作直接解决 NAPA 以及 NIA-AD/ADRD 里程碑设定的目标 科学; (3) 它将确定种族特异性生物标志物轨迹是否合适，最后，(4) 它将 生成数据和方法，以增加西班牙裔美国人参加 AT(N) 定义的临床试验的人数 AD 的范围（一级、二级和三级预防）始于初级保健机构。

项目成果

Characterizing plasma NfL in a community-dwelling multi-ethnic cohort: Results from the HABLE study.

在社区居住的多种族队列中表征血浆NFL：Hable研究的结果。

• DOI: 10.1002/alz.12404
• 发表时间: 2022-03
• 期刊: Alzheimer's & dementia : the journal of the Alzheimer's Association

Characterization of Mild Cognitive Impairment and Dementia among Community-Dwelling Mexican Americans and Non-Hispanic Whites.

• DOI: 10.3233/jad-220300
• 发表时间: 2022
• 期刊: Journal of Alzheimer's disease : JAD
• 作者: O'Bryant SE;Petersen M;Hall J;Johnson LA;Barber R;Phillips N;Braskie MN;Yaffe K;Rissman R;Toga A;HABS-HD Study Team
• 通讯作者: HABS-HD Study Team

A blood screening tool for detecting mild cognitive impairment and Alzheimer's disease among community-dwelling Mexican Americans and non-Hispanic Whites: A method for increasing representation of diverse populations in clinical research.

• DOI: 10.1002/alz.12382
• 发表时间: 2022-01
• 期刊: Alzheimer's & dementia : the journal of the Alzheimer's Association
• 作者: O'Bryant SE;Zhang F;Petersen M;Hall JR;Johnson LA;Yaffe K;Mason D;Braskie M;Barber RA;Rissman RA;Mapstone M;Mielke MM;Toga AW;HABLE Study Team
• 通讯作者: HABLE Study Team

The Link between APOE4 Presence and Neuropsychological Test Performance among Mexican Americans and Non-Hispanic Whites of the Multiethnic Health & Aging Brain Study - Health Disparities Cohort.

• DOI: 10.1159/000521898
• 发表时间: 2022
• 期刊: Dementia and geriatric cognitive disorders
• 影响因子: 2.4

Neurodegeneration from the AT(N) framework is different among Mexican Americans compared to non-Hispanic Whites: A Health & Aging Brain among Latino Elders (HABLE) Study.

• DOI: 10.1002/dad2.12267
• 发表时间: 2022
• 期刊: Alzheimer's & dementia (Amsterdam, Netherlands)
• 作者: O'Bryant SE;Zhang F;Petersen M;Hall J;Johnson LA;Yaffe K;Braskie M;Rissman RA;Vig R;Toga AW;HABLE Study Team
• 通讯作者: HABLE Study Team